<SEC-DOCUMENT>0001615219-22-000153.txt : 20221212
<SEC-HEADER>0001615219-22-000153.hdr.sgml : 20221212
<ACCEPTANCE-DATETIME>20221212182933
ACCESSION NUMBER:		0001615219-22-000153
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20221103
FILED AS OF DATE:		20221212
DATE AS OF CHANGE:		20221212

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Rosenblum Mark J
		CENTRAL INDEX KEY:			0001329154

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		221458168

	MAIL ADDRESS:	
		STREET 1:		3990 SPRING VALLEY ROAD, APT. 1218
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75244

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>wf-form4a_167088775808803.xml
<DESCRIPTION>FORM 4/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2022-11-03</periodOfReport>

    <dateOfOriginalSubmission>2022-11-07</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001615219</issuerCik>
        <issuerName>Salarius Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>SLRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001329154</rptOwnerCik>
            <rptOwnerName>Rosenblum Mark J</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SALARIUS PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2450 HOLCOMBE BLVD., SUITE X</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>77021</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Exec VP Finance, CFO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-11-03</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>5</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value>E</value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1488</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.734</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>7419</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 7,314 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 1,488 shares of common stock.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Mark J. Rosenblum</signatureName>
        <signatureDate>2022-12-12</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
